TRBV7-4: A Potential Drug Target and Biomarker for T Cell Receptor尾 Variable 7-4

Target Name: TRBV7-4

NCBI ID: G28594

TRBV7-4

Other Name(s): T cell receptor beta variable 7-4 | TCRBV7S4 | TCRBV6S8A2T | TRBV74

TRBV7-4: A Potential Drug Target and Biomarker for T Cell Receptor尾 Variable 7-4

T cells are a crucial immune system cell that play a vital role in fighting off infections and cancer. They are able to recognize and respond to foreign substances in the body, thanks to their T cell receptor (TCR), which is a protein that recognizes specific molecules. One of the most well-known TCRs is called TRBV7-4, and it has been identified as a potential drug target and biomarker for various diseases.

TRBV7-4 is a type of T cell receptor that is expressed in many different tissues throughout the body, including the skin, hair, and nails. It is also involved in cell signaling and has been shown to play a role in various immune responses. One of its most well-known functions is its role in cancer immune surveillance. Studies have shown that TRBV7-4 is often expressed in cancer tissues and that targeting this receptor has the potential to be an effective cancer treatment.

In addition to its potential as a cancer treatment, TRBV7-4 has also been identified as a potential drug target for other diseases. One of the ways that TRBV7-4 may be used as a drug is by targeting its role in inflammation. Chronic inflammation is a major risk factor for a variety of diseases, including heart disease, diabetes, and cancer. By targeting TRBV7-4, drugs may be able to reduce inflammation and improve overall health.

Another potential use for TRBV7-4 as a drug target is its role in autoimmune diseases. These diseases occur when the immune system becomes imbalanced and begins to attack healthy cells and tissues. TRBV7-4 is involved in the regulation of immune responses, and targeting this receptor may be able to treat autoimmune diseases.

TRBV7-4 has also been identified as a potential biomarker for certain diseases. This means that measuring levels of TRBV7-4 in the body can be used as a way to diagnose or monitor the progression of certain diseases. For example, high levels of TRBV7-4 have been shown to be associated with the development of certain types of cancer. By detecting levels of TRBV7-4 in cancer tissues, doctors may be able to determine the effectiveness of certain treatments and monitor for any potential side effects.

In conclusion, TRBV7-4 is a potential drug target and biomarker for a variety of diseases. Its role in cancer immune surveillance and its potential as a drug target make it an attractive target for researchers and doctors. Further studies are needed to fully understand the effects of TRBV7-4 and its potential as a drug.

Protein Name: T Cell Receptor Beta Variable 7-4

Functions: V region of the variable domain of T cell receptor (TR) beta chain that participates in the antigen recognition (PubMed:24600447). Alpha-beta T cell receptors are antigen specific receptors which are essential to the immune response and are present on the cell surface of T lymphocytes. Recognize peptide-major histocompatibility (MH) (pMH) complexes that are displayed by antigen presenting cells (APC), a prerequisite for efficient T cell adaptive immunity against pathogens (PubMed:25493333). Binding of alpha-beta TR to pMH complex initiates TR-CD3 clustering on the cell surface and intracellular activation of LCK that phosphorylates the ITAM motifs of CD3G, CD3D, CD3E and CD247 enabling the recruitment of ZAP70. In turn ZAP70 phosphorylates LAT, which recruits numerous signaling molecules to form the LAT signalosome. The LAT signalosome propagates signal branching to three major signaling pathways, the calcium, the mitogen-activated protein kinase (MAPK) kinase and the nuclear factor NF-kappa-B (NF-kB) pathways, leading to the mobilization of transcription factors that are critical for gene expression and essential for T cell growth and differentiation (PubMed:23524462). The T cell repertoire is generated in the thymus, by V-(D)-J rearrangement. This repertoire is then shaped by intrathymic selection events to generate a peripheral T cell pool of self-MH restricted, non-autoaggressive T cells. Post-thymic interaction of alpha-beta TR with the pMH complexes shapes TR structural and functional avidity (PubMed:15040585)

The "TRBV7-4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRBV7-4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets